Latest News

Allergan to License UroGen Pharma’s RTGel Drug Delivery System For $17.5 Mln Upfront Payment & Milestones

Allergan (AGN) sealed a deal with Israeli-based UroGen Pharma to license worldwide rights to UroGen’s RTGel drug delivery system technology, UroGen reported pre-market Friday. Under the agreement, Allergan agreed to make a $17.5 million upfront payment to UroGen as well as potential development and commercial milestones and royalties on netRead More

Syngenta ADRs Edge Lower as Suitor ChemChina Said in Merger Talks With Sinochem Group

Syngenta AG (SYT) American depository shares were lower over 1% in recent pre-market trade as Reuters cited unnamed people with knowledge of the matter as saying that China National Chemicals Corp, which is seeking to take over the Swiss crop protection and seeds company, is in talks to merge withRead More

Wells Fargo Q3 EPS, Revenue Top Expectations; Shares Edge Higher Pre-Bell

Wells Fargo (WFC) inched higher in premarket trading after the bank holding company reported Q3 results that beat Wall Street expectations. Shares rose as much as 0.7%. EPS decreased to $1.03 in the September quarter, from $1.05 in the year-ago period. That beat the $1.01 average estimate of analysts polledRead More

Ulta Salon, Cosmetics & Fragrance Gains After Raising Q3, Full-Year and Long-Term Sales Guidance

Ulta Salon, Cosmetics & Fragrance (ULTA) stock rose more than 7% after the beauty products company said it expects Q3 comparable sales and earnings to be higher than its previous guidance, raised its full-year forecast and expectations for long-term revenue growth. For Q3, the company said it expects sales toRead More

Stock Indexes Decline as Lowest Average Claims in 43 Years Gives Fed Rate-Hike Ammunition

Stock indexes declined after the average number of Americans filing jobless claims fell to the lowest level in almost 43 years, giving the Federal Reserve more ammunition to raise interest rates before the end of the year. The rolling four-week average of jobless claims dropped to 249,250, the lowest sinceRead More

ContraVir Pharmaceuticals Stock Jumps on Positive Results From Hepatitis B-Drug Trial

ContraVir Pharmaceuticals Inc (CTRV) stock jumped almost 28% after the company presented positive interim data for CMX157, an equivalent to tenofovir, to treat hepatitis B. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to Gilead’s (GILD) tenofovir disoproxil fumarate, known as Viread.Read More